{{Drugbox
| verifiedrevid = 414168979
| IUPAC_name = 9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3''H'',6''H'',7''H''-pyrrolo[3,2-''f'']quinolin-7-one
| image = LGD-3303.svg
| width = 250

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| index_label =
| index2_label =
| CAS_number = 917891-35-1
| CAS_number2 = 1196133-39-7
| ATC_prefix =  
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 25195253
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7N4E1X2RJM
| ChemSpiderID      = 35143239

<!--Chemical data-->
| chemical_formula =  
| C=16 | H=14 | Cl=1 | F=3 | N=2 | O=1 
| molecular_weight = 342.743 g/mol
| smiles = CCC1=C(C2=C(N1CC(F)(F)F)C=CC3=C2C(=CC(=O)N3)Cl)C
| StdInChI = 1S/C16H14ClF3N2O/c1-3-11-8(2)14-12(22(11)7-16(18,19)20)5-4-10-15(14)9(17)6-13(23)21-10/h4-6H,3,7H2,1-2H3,(H,21,23)
| StdInChIKey       = OMXGOGXEWUCLFI-UHFFFAOYSA-N
}}

'''LGD-3303''' is a drug which acts as a [[selective androgen receptor modulator]] (SARM), with good oral bioavailability. It is a selective agonist for the [[androgen receptor]], producing [[functional selectivity]] with effective dissociation of [[anabolic]] and [[androgen]]ic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects.<ref>{{cite journal|first1=Eric G.|last1=Vajda|first2=Francisco J.|last2=López|first3=Peter|last3=Rix|first4=Robert|last4=Hill|title=Pharmacokinetics and Pharmacodynamics of LGD-3303 [9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3''H''-pyrrolo-[3,2-''f'']quinolin-7(6''H'')-one], an Orally Available Nonsteroidal-Selective Androgen Receptor Modulator|url=http://jpet.aspetjournals.org/content/328/2/663.full|journal=Journal of Pharmacology and Experimental Therapeutics|date=1 February 2009|issn=1521-0103|pages=663–670|volume=328|issue=2|doi=10.1124/jpet.108.146811|pmid=19017848|first5=Yanling|last5=Chen|first6=Kyoung-Jin|last6=Lee|first7=Z.|last7=O'Brien|first8=William Y.|last8=Chang|first9=Martin D.|last9=Meglasson|first10=Yong-Hee|last10=Lee}}</ref> It has been investigated as a possible treatment for [[osteoporosis]], and was shown in animal studies to enhance the effectiveness of a [[bisphosphonate]] drug.<ref>{{cite journal|first1=Eric G|last1=Vajda|first2=Aimee|last2=Hogue|first3=Kimberly N|last3=Griffiths|first4=William Y|last4=Chang|title=Combination Treatment With a Selective Androgen Receptor Modulator q(SARM) and a Bisphosphonate Has Additive Effects in Osteopenic Female Rats|url=http://onlinelibrary.wiley.com/doi/10.1359/jbmr.081007/full|journal=Journal of Bone and Mineral Research|date=1 February 2009|issn=1523-4681|pages=231–240|volume=24|issue=2|doi=10.1359/jbmr.081007|pmid=18847323|first5=Kelven|last5=Burnett|first6=Yanling|last6=Chen|first7=Keith|last7=Marschke|first8=Dale E|last8=Mais|first9=Bijan|last9=Pedram|first10=Yixing|last10=Shen|first11=Arjan|last11=van Oeveren|first12=Lin|last12=Zhi|first13=Francisco J|last13=López|first14=Martin D|last14=Meglasson}}</ref>

== References ==
{{Reflist}}

{{Androgen receptor modulators}}

[[Category:Hormonal agents]]
[[Category:Indoles]]
[[Category:Lactams]]
[[Category:Organochlorides]]
[[Category:Organofluorides]]
[[Category:Selective androgen receptor modulators]]
[[Category:Trifluoromethyl compounds]]


{{genito-urinary-drug-stub}}